Acute myeloid leukemia
Conditions
Interventions
Study Group:IDA
Sponsors
Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed elderly AML is confirmed by bone marrow morphology and immunology assay; 2. APL is excluded by bone marrow morphology or molecular level tests; 3. Patient is between the age of 60-75 years (including 60 and 75); 4. Bone marrow morphology demonstrates the features of active bone marrow hyperplasia; 5. Patient meets the conditions of Pre-treatment risk assessment stratification scale ("suitable " group) for elderly AML (non-M3); 6. Obtained an Informed Consent Form signed by patient or their families.
Exclusion criteria
Exclusion criteria: 1. APL patients; 2. Re-treated patient; 3. Low bone marrow hyperplasia promoted by bone marrow cytological examination; 4. Allergy to any drug presented in study protocol; 5. Obvious contraindications to anthracycline chemotherapy drugs; 6. Patient meets the conditions of "not suitable" and "unfit for chemotherapy" in the Pre-treatment risk assessment stratification scale for elderly AML (non-M3); 7. Unable to understand or comply with the study protocol; 8. Previous intolerance or allergy to the similar drugs; 9. Patients below the age of 60 or over 75 (60 and 75 are not included); 10. Participating in other clinical investigation simultaneously; 11. Having any issue that may hinder the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Remission;Minimal residual disease; | — |
Countries
China
Contacts
Public ContactJunmin Li
Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed